Mochi Health BBB and Consumer-Complaint Trends: What the Data Actually Shows

What Is Mochi Health and How Does Its Model Work?

Mochi Health is a weight-management telehealth platform founded in 2022 that connects patients with licensed clinicians to prescribe FDA-approved and compounded GLP-1 receptor agonists, including semaglutide and tirzepatide. The platform operates a dual-track model: it attempts insurance billing for covered medications while also offering a cash-pay membership tier.

The Dual-Track Billing Model

The insurance-plus-cash approach creates a specific operational complexity that directly relates to many consumer complaints. When insurance denies coverage, the platform shifts patients to cash-pay compounded semaglutide or tirzepatide. This transition is not always communicated clearly at sign-up, and several BBB complaint narratives describe unexpected charges after an insurance denial.

The membership fee of approximately $99 per month covers clinician access and the telehealth visit itself. Medication costs are separate. For patients who end up on compounded semaglutide at a 503B outsourcing facility, the total monthly outlay can reach $200 to $450 depending on dose.

Regulatory Framework the Platform Operates Under

Mochi Health prescribers are licensed physicians, nurse practitioners, and physician assistants operating under state telehealth laws. The company is not a pharmacy. Prescriptions are routed to third-party compounding pharmacies or retail pharmacies. Because the pharmacy relationship is outsourced, the FDA's oversight of the compounded products themselves falls on those pharmacies, not on Mochi Health directly. The FDA's guidance on 503A and 503B compounding pharmacies sets the legal boundaries within which those partner facilities operate [1].

Mochi Health BBB Profile: Ratings, Complaints, and Patterns

The Better Business Bureau profile for Mochi Health shows an unaccredited status as of July 2025. BBB accreditation is voluntary and paid, so the absence of accreditation is not itself a red flag. What is more informative is the complaint count, the complaint categories, and how the company responds.

Complaint Volume and Resolution Rate

BBB complaint counts for telehealth weight-loss platforms rose significantly between 2022 and 2024, coinciding with the GLP-1 demand surge. Mochi Health's BBB page has accumulated complaints numbering in the dozens rather than hundreds, which places it in a moderate range relative to larger competitors like Ro and Hims/Hers, both of which carry complaint counts in the hundreds. The Federal Trade Commission tracks consumer complaints about subscription services and recurring billing broadly, and the FTC's 2023 data showed telehealth subscription billing as a rising category of dispute [2].

The Four Main Complaint Categories

Breaking the complaints into categories reveals a clearer pattern:

1. Billing and subscription cancellation. The most common complaint type involves difficulty canceling the membership, continued charges after cancellation requests, or charges occurring before a clinician visit is completed. These are operational complaints, not clinical safety complaints.

2. Prescription delay or non-fulfillment. Patients report submitting for a prescription and waiting two to six weeks without receiving medication. Some of these delays trace to pharmacy-side compounding backlogs; others appear to be prior-authorization delays on the insurance track.

3. Difficulty reaching customer support. Multiple complaints describe a slow ticket-based response system rather than live phone support. This is consistent with a lean, asynchronous telehealth model.

4. Clinical disagreement or denial. A smaller subset of complaints involves patients who were denied a GLP-1 prescription after paying the membership fee. Clinicians have the legal and ethical obligation to decline prescriptions that fall outside appropriate criteria, so this category is not inherently a problem, though the fee-before-visit structure does create friction.

How Mochi Health Responds to BBB Complaints

Response quality matters as much as complaint volume. When a company answers BBB complaints quickly and offers refunds or resolution, it signals a functional customer-service operation. Mochi Health's BBB page shows a mix of responses. Some complaints are marked resolved; others remain open for extended periods. No pattern of ignoring complaints entirely has been documented, but response times are inconsistent.

Is Mochi Health Legit? Evaluating the Clinical and Regulatory Evidence

"Legit" in a telehealth context covers at least three distinct questions: Is the company operating within the law? Are its prescribers real, licensed clinicians? Are the medications it delivers genuine pharmaceutical-grade products?

Prescriber Legitimacy

Mochi Health publishes its clinician roster and states that all prescribers hold active state licenses. Patients can independently verify any prescriber's license through the relevant state medical or nursing board website. The National Practitioner Data Bank (NPDB) is accessible to patients in limited form; state licensing databases are fully public. No systematic pattern of unlicensed prescribing at Mochi Health has appeared in state board disciplinary databases as of this review.

Medication Legitimacy

This is the more complex question. FDA-approved branded semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are tightly regulated and carry no authenticity concerns when dispensed by a licensed retail pharmacy. Compounded semaglutide and tirzepatide are different. The FDA does not approve compounded drugs and does not verify their potency or sterility on a pre-market basis [3]. In November 2024, the FDA declared the shortage of semaglutide resolved, which formally ended the legal basis for most 503A pharmacies to compound semaglutide. Many telehealth platforms, including Mochi Health, continued prescribing compounded semaglutide through early 2025 while litigation over the shortage designation was ongoing [4].

Patients using Mochi Health's compounded-medication track should ask which specific compounding pharmacy fills their prescription and verify that pharmacy's registration status through the FDA's database of registered outsourcing facilities [3].

LegitScript and Pharmacy Verification

LegitScript is an independent certification body that verifies online pharmacies. Because Mochi Health itself is not a pharmacy, it does not hold a LegitScript pharmacy certification. This is expected and appropriate. The pharmacies Mochi Health routes prescriptions to may or may not carry LegitScript accreditation. Patients can check any pharmacy's status at the LegitScript verification portal. The FDA's BeSafeRx program offers a parallel consumer-facing lookup [5].

Compounded GLP-1 Safety Context

Complaints about compounded medications are not unique to Mochi Health. The FDA issued a safety alert in January 2024 noting reports of adverse events associated with compounded semaglutide products, including nausea, vomiting, and, in some cases, dosing errors linked to incorrect concentration labeling [6]. The agency noted that these reports did not allow it to confirm whether the products came from registered 503B facilities or from smaller 503A pharmacies.

What the STEP-1 Trial Tells Us About Legitimate Semaglutide

In STEP-1 (N=1,961), semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% with placebo (P<0.001) [7]. That benchmark exists only for pharmaceutical-grade semaglutide manufactured by Novo Nordisk under controlled GMP conditions. There is no published efficacy trial for any compounded semaglutide formulation. Patients using Mochi Health on the compounded track are not getting the product that achieved those results in STEP-1; they are getting a product that contains the same active-ingredient molecule (the free-base acid or salt form of semaglutide) produced by a pharmacy under entirely different manufacturing conditions.

Tirzepatide Data for Comparison

In SURMOUNT-1 (N=2,539), tirzepatide 15 mg produced 20.9% mean body-weight reduction at 72 weeks versus 3.1% placebo [8]. The same caveat applies: this result is for Eli Lilly's branded tirzepatide, not for compounded versions. The FDA declared tirzepatide shortages resolved in December 2024.

State-Level Oversight and Telehealth Prescribing Standards

State medical boards govern prescribing practices within their jurisdictions. Texas, Florida, and California, three of Mochi Health's largest markets by population, each maintain searchable disciplinary action databases.

Relevant Prescribing Standards

The Federation of State Medical Boards (FSMB) published its Model Policy for the Appropriate Use of Telemedicine Technologies in the Practice of Medicine, which states that "the standard of care is not altered by the fact that the patient interaction occurs via telemedicine rather than in-person." [9] Prescribing GLP-1 medications without an adequate history, a reviewed BMI, and documentation of comorbidities would fall below that standard.

Mochi Health's intake process collects BMI, weight history, and comorbidity data through a patient questionnaire and asynchronous clinician review. Whether that process meets the "adequate evaluation" threshold is a matter of ongoing debate in state-level telehealth policy circles. The American Association of Clinical Endocrinologists' 2023 Obesity Clinical Practice Guidelines recommend that obesity pharmacotherapy be initiated when BMI is 30 or above, or 27 or above with at least one weight-related comorbidity [10]. Mochi Health's stated eligibility criteria align with this standard on paper.

No Public Sanctions as of July 2025

A review of publicly accessible state medical board disciplinary databases in California, Texas, Florida, New York, and Illinois found no sanctions, probations, or license revocations connected to Mochi Health's clinicians in relation to their work on the platform. That is a meaningful data point. It does not guarantee future compliance, but it distinguishes Mochi Health from telehealth platforms that have faced formal regulatory action.

FDA Oversight and Enforcement Context

The FDA does not regulate telehealth platforms directly as medical-device or drug manufacturers unless those platforms are making drug-marketing claims. The agency regulates the medications and the pharmacies. From that standpoint, the enforcement risk to Mochi Health flows through its pharmacy partners.

The FDA's 2024 and 2025 Compounding Alerts

The FDA's January 2024 safety alert on compounded semaglutide [6] and its subsequent warning letters to specific compounding pharmacies in 2024 are the most directly relevant enforcement actions in this space, though none named Mochi Health. The agency's broader crackdown on telehealth-adjacent compounders is documented in the FDA's compounding warning letter database [11].

Patients who receive compounded semaglutide or tirzepatide through any platform, including Mochi Health, can report adverse events through FDA MedWatch at www.fda.gov/safety/medwatch [12].

FTC Scrutiny of Subscription Billing Practices

The FTC's "Click-to-Cancel" rule, finalized in October 2024, requires subscription services to make cancellation as easy as sign-up [13]. Telehealth platforms with monthly membership models fall within scope. Mochi Health's cancellation complaints on the BBB predate the rule's effective date; post-effective compliance has not yet been independently audited.

How to Evaluate Any Telehealth Weight-Loss Platform

Mochi Health is one of dozens of GLP-1 telehealth platforms operating in 2025. The following evaluation framework applies broadly:

Step 1: Verify the Prescriber

Use your state medical board's public lookup tool to confirm the clinician assigned to your account holds an active, unsanctioned license. This takes under three minutes.

Step 2: Identify the Pharmacy

Ask specifically which pharmacy will compound or dispense your medication. Verify that pharmacy's DEA registration and, for compounders, its FDA 503B registration if it claims outsourcing-facility status. A pharmacy that refuses to identify itself to a patient is a serious warning sign.

Step 3: Read the Billing Terms Before Paying

Mochi Health, like most subscription telehealth services, charges the membership fee before a clinician reviews eligibility. Know the refund policy and the cancellation process in writing before entering payment information.

Step 4: Check Complaint Databases Independently

The BBB is one data source. Others include the FTC Consumer Sentinel database (accessible to consumers via ftc.gov/complaint), state attorney general complaint portals, and Google and Trustpilot reviews. No single source is complete.

Step 5: Confirm Medication Authenticity at the Pharmacy Level

If you receive a compounded injectable, you have the right to request a certificate of analysis (COA) from the compounding pharmacy. A COA from an accredited third-party lab confirms the potency and absence of contamination in your specific batch.

What Patients Should Know About GLP-1 Efficacy Regardless of Platform

The clinical evidence for weight loss with GLP-1 receptor agonists is strong. STEP-1 demonstrated 14.9% body-weight reduction with semaglutide 2.4 mg over 68 weeks [7]. The SELECT trial (N=17,604) showed semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% versus placebo over a mean follow-up of 33.3 months in patients with established cardiovascular disease and overweight or obesity (P<0.001) [14]. Those outcomes depend on pharmaceutical-grade medication, consistent dosing, and clinical monitoring.

The Endocrine Society's 2023 Clinical Practice Guideline on Obesity Pharmacotherapy states directly that "pharmacotherapy should be used as an adjunct to, not a replacement for, lifestyle intervention" [15]. Platforms like Mochi Health that offer medication without structured behavioral support are providing only part of what the guideline recommends.

Patients who achieve access to genuine semaglutide or tirzepatide through Mochi Health and maintain engagement with their assigned clinician may achieve meaningful weight loss. Patients who receive subpotent compounded products, lose access due to billing disputes, or disengage because of poor customer service will not. The complaint data suggests the latter outcome is more common than the platform's marketing implies.